Acura Pharmaceuticals Inc. has recently amended its existing financing agreement with Abuse Deterrent Pharma, LLC. The amended loan schedule, part of a secured promissory note initially dated November 10, 2022, outlines a series of additional loans granted to Acura Pharmaceuticals. The latest addition includes Loan #38, dated June 20, 2025, amounting to $100,000, which brings the total aggregated principal to $8,194,279. This series of loans, from the original note and subsequent additional loans, reflects Acura Pharmaceuticals' ongoing strategic financial maneuvers to support its operational and development activities.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.